Effects of persistent cannabis use on depression, psychosis, and suicidality following cannabis‐induced psychosis: A longitudinal study DOI
Valerio Ricci, Domenico De Berardis, Giovanni Martinotti

et al.

American Journal on Addictions, Journal Year: 2025, Volume and Issue: unknown

Published: May 14, 2025

Abstract Background and Objectives Cannabis use is associated with psychotic disorder onset exacerbation. This study examines how continued cannabis affects depressive symptoms, suicidal behaviors following cannabis‐induced first‐episode psychosis (FEP). Methods Sixty‐five participants (aged 16–50 years) FEP were recruited from psychiatric inpatient facilities in northern Italy. Participants categorized into two groups: non‐cannabis users (NCU) (CU), based on substance during the 9‐month follow‐up. Twenty‐one (32.3%) lost to follow‐up, a final sample of 44 subjects (NCU = 22, CU 22). Assessments conducted at baseline, 3 months, 9 months using PANSS, CDSS, SSI, GAF scales). Results exhibited persistently higher depression (CDSS) suicidality (SSI) scores than NCU throughout significant differences both (CDSS: p .000006; SSI: < .001) .0000001; .001). Positive symptoms improved groups, though showed slower recovery relapse rates (59.9% vs. 18.8%). PANSS positive subscale remained significantly ( .0002). only .024 months). Discussion Conclusions Continued adversely patients, while cessation clinical outcomes. Scientific Significance tracks suicidality, manifestations FEP, demonstrating that treatment‐resistant even when improve, highlighting need for integrated approaches.

Language: Английский

An overview of the challenges with the differential diagnosis of schizotypal personality disorder DOI

Katherine Raffensperger,

Philip D. Harvey

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 14, 2025

Schizotypal personality disorder (SPD) has a long history and there is still considerable ongoing research. Although are overlapping features of SPD other disorders, the full constellation schizotypal broader. The longitudinal course variable, with differences in trajectory manifesting lifelong clinical significance. Particularly important relationship between prodromal states that may result an eventual diagnosis psychosis. This review covers differential SPD, including older conceptualization 'borderline schizophrenia.' Clinical, cognitive, functional, brain imaging, genetic implications age at onset method ascertainment condition reviewed. Differences psychometrically identified schizotypy, clinically diagnosed psychiatric conditions described. A comprehensive literature search using MEDLINE (via PubMed) did not specify date range, to capture scope unique critical for persistence diagnosis. When late adolescence, some individuals develop psychosis, remit, others have persistent, symptoms. Predictors conversion psychosis been but no proven treatments.

Language: Английский

Citations

0
Effects of persistent cannabis use on depression, psychosis, and suicidality following cannabis‐induced psychosis: A longitudinal study DOI
Valerio Ricci, Domenico De Berardis, Giovanni Martinotti

et al.

American Journal on Addictions, Journal Year: 2025, Volume and Issue: unknown

Published: May 14, 2025

Abstract Background and Objectives Cannabis use is associated with psychotic disorder onset exacerbation. This study examines how continued cannabis affects depressive symptoms, suicidal behaviors following cannabis‐induced first‐episode psychosis (FEP). Methods Sixty‐five participants (aged 16–50 years) FEP were recruited from psychiatric inpatient facilities in northern Italy. Participants categorized into two groups: non‐cannabis users (NCU) (CU), based on substance during the 9‐month follow‐up. Twenty‐one (32.3%) lost to follow‐up, a final sample of 44 subjects (NCU = 22, CU 22). Assessments conducted at baseline, 3 months, 9 months using PANSS, CDSS, SSI, GAF scales). Results exhibited persistently higher depression (CDSS) suicidality (SSI) scores than NCU throughout significant differences both (CDSS: p .000006; SSI: < .001) .0000001; .001). Positive symptoms improved groups, though showed slower recovery relapse rates (59.9% vs. 18.8%). PANSS positive subscale remained significantly ( .0002). only .024 months). Discussion Conclusions Continued adversely patients, while cessation clinical outcomes. Scientific Significance tracks suicidality, manifestations FEP, demonstrating that treatment‐resistant even when improve, highlighting need for integrated approaches.

Language: Английский

Citations

0